BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more
BGI Genomics Co Ltd (300676) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-3.08 Million) by net assets (CN¥9.37 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BGI Genomics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how BGI Genomics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BGI Genomics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BGI Genomics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Motor Oil (Hellas) Corinth Refineries S.A
PINK:MOHCF
|
0.123x |
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
0.038x |
|
Dalrymple Bay Infrastructure Ltd
AU:DBI
|
-0.005x |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
0.084x |
|
Intuitive Machines Inc.
NASDAQ:LUNR
|
-0.029x |
|
Century Communities Inc
NYSE:CCS
|
0.083x |
|
FUYO GENERAL LEASE CO.LTD
F:FXL
|
N/A |
|
0LUG
LSE:0LUG
|
N/A |
Annual Cash Flow Conversion Efficiency for BGI Genomics Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of BGI Genomics Co Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.27 Billion | CN¥95.72 Million | 0.010x | -74.73% |
| 2023-12-31 | CN¥10.00 Billion | CN¥408.77 Million | 0.041x | +206.31% |
| 2022-12-31 | CN¥10.22 Billion | CN¥136.38 Million | 0.013x | -94.91% |
| 2021-12-31 | CN¥9.44 Billion | CN¥2.48 Billion | 0.262x | -56.13% |
| 2020-12-31 | CN¥6.03 Billion | CN¥3.60 Billion | 0.598x | +1073.36% |
| 2019-12-31 | CN¥4.40 Billion | CN¥224.25 Million | 0.051x | +1375.28% |
| 2018-12-31 | CN¥4.25 Billion | CN¥14.69 Million | 0.003x | -93.51% |
| 2017-12-31 | CN¥4.26 Billion | CN¥226.57 Million | 0.053x | -21.51% |
| 2016-12-31 | CN¥3.45 Billion | CN¥234.07 Million | 0.068x | -34.62% |
| 2015-12-31 | CN¥3.17 Billion | CN¥328.68 Million | 0.104x | +1961.44% |
| 2014-12-31 | CN¥1.47 Billion | CN¥-8.16 Million | -0.006x | -109.08% |
| 2013-12-31 | CN¥597.94 Million | CN¥36.70 Million | 0.061x | -87.27% |
| 2012-12-31 | CN¥150.37 Million | CN¥72.49 Million | 0.482x | -- |